http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Salarius Pharmaceuticals, Inc. (SLRX) Completes SP-3164 Related Meeting with FDA, Plans to Submit IND in 2023
-
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
-
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
-
Salarius Pharmaceuticals, Inc. (SLRX) Prices 9.34M Share Direct Offering at $0.25/sh
-
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
-
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
-
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
-
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
-
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
-
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
-
Salarius Pharmaceuticals, Inc. (SLRX) Acquires Targeted Protein Degradation Portfolio from DeuteRx
-
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
-
Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"
-
Salarius Pharmaceuticals, Inc. (SLRX) Announced Achievement of Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
-
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
-
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
-
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
-
Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
-
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
-
Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Thera
-
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
-
Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
-
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
-
Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference
-
Salarius Pharmaceuticals, Inc. (SLRX) Announces Research Partnership With Fox Chase Cancer Center
-
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
-
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
-
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
-
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
-
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
-
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
-
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
-
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit
-
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
-
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
-
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
-
Salarius Pharmaceuticals (SLRX) Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
-
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
-
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
-
Salarius Pharmaceuticals, Inc. (SLRX) Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology
-
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights
-
Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results
-
Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting
-
Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting
-
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results
-
Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results
-
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference
-
Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

